Teva Pharmaceutical Industries Limited, together with its subsidiaries and associated companies, engages in the development, manufacture, marketing and distribution of generic, specialty, and other pharmaceutical products. Strategy The key elements of the company’s strategy include solidifying its foundation and driving organic growth; transforming its generics business; focusing on key growth markets; maintaining Copaxone and other key specialty products; solidifying leadership positions in its core therapeutic areas; and pursuing strategic business development initiatives. Segments The company operates in two segments, Generic Medicines and Specialty Medicines. Generic Medicines This segment includes chemical and therapeutic equivalents of originator medicines. The company develops, manufactures and sells Generic Medicines in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. It offers a range of basic chemical entities, as well as specialized product families, such as sterile products, hormones, narcotics, high-potency drugs and cytotoxic substances, in both parenteral and solid dosage forms. The company produces approximately 300 active pharmaceutical ingredients (APIs) for its own use and for sale to third parties in many therapeutic areas. APIs used in pharmaceutical products are subject to regulatory oversight by national health authorities. The company utilizes various production technologies, including chemical synthesis, semi-synthetic fermentation, enzymatic synthesis, high potency manufacturing, plant extract technology and peptides synthesis. United States: The company is a generic drug company in the United States. It markets approximately 370 generic products in approximately 1,100 dosage strengths and packaging sizes, including oral, injectable and inhaled products. Its growth strategy focuses on a portfolio of products that would provide added value to its customers, payors and patients, utilizing new and advanced technologies. In most other markets in which the company operates, it uses a marketing model, offering a range of generic, specialty and over-the-counter (OTC) products. Europe: The company operates as the generic pharmaceutical company in Europe. Its strategy for generics medicines in Europe is to seek sustainable and profitable growth by differentiated investment levels in different countries. Rest of the World (ROW) Markets: The company’s ROW markets include all countries other than the United States and those included under Europe. Its key ROW markets are Japan, Canada, Venezuela and Russia. The company has an agreement with Takeda Pharmaceutical Company Limited (Takeda) to form a business venture to provide Generic Medicines in Japan. Teva would have a 51% stake and Takeda would have 49% in the business venture. The company markets generic products to retail chains, retail buying groups and independent pharmacies, reaching approximately 8,800 outlets across Canada. The company operates in Venezuela, with a product portfolio in a range of therapeutic areas. The company’s products are mainly marketed as generic and branded generics medicines. In Russia, the company markets a portfolio of products. Specialty Medicines This segment includes franchises, most significantly its core therapeutic areas of central nervous system (CNS) medicines, such as Copaxone, Azilect, Nuvigil and Zecuity and of respiratory medicines, such as ProAir hydrofluoroalkane (HFA) and QVAR. This segment includes other therapeutic areas, such as oncology medicines, including Treanda, women’s health and selected other areas. This segment focuses on delivering solutions to patients and providers through medicines, devices and services in key regions and markets around the world, includes its core therapeutic areas of CNS (with an emphasis on multiple sclerosis, neurodegenerative disorders, movement disorders and pain care) and respiratory medicines (with a focus on asthma and chronic obstructive pulmonary disease (COPD)). The company also has specialty products in oncology, women’s health, and selected other areas. Central
teva pharmaceutical-sp adr
5 Basel Street
PO Box 3190
Petach Tikva, 49131
Phone: 972 3 926 7267
Fax: 972 3 923 4050www.tevapharm.com
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|Abbott Laboratories||$38.89 USD||+0.21|
|Allergan plc||$232.36 USD||+4.51|
|AstraZeneca PLC||4,012 GBp||-3.00|
|Biogen Inc||$282.00 USD||+2.30|
|Eli Lilly & Co||$75.52 USD||+0.98|
|View Industry Companies|
Sponsored Financial Commentaries
To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.